Company intelligence / Profile preview

Bio-protocol

Ownership: Private
Development stage: Other

Overview

Bio Protocol has launched an active platform supporting over 8 BioDAOs with a cumulative market cap exceeding $300M. Over $7.37M has been deployed into research via these DAOs. The platform’s acceleration program has led to successful fundraising rounds—one recent DAO launch was 13x oversubscribed ($6.8M raised). Its tokenized IP portfolio is valued at more than $43M as of late 2024[5].

Therapeutic areas: Rare DiseasesOtherDermatologyNeurologyWomen's Health
Modalities: Small moleculeBiologicGene therapyCell therapymRNA-based drugsPeptides
Industry: Investors

Partnerships

VitaDAOPfizer VenturesNewcastle UniversityImperial College LondonResearchHubPump.ScienceBinance Labs

Beyond the preview

Go deeper on Bio-protocol.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bio-protocol.

Explore the full profile